Moderna and MSD’s cancer vaccine plus Keytruda boosts RFS in melanoma study
A combination of Moderna and MSD's personalised cancer vaccine, intismeran autogene, and MSD’s stalwart oncology drug, Keytruda (pembrolizumab), has significantly…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Speech biomarkers offer new lease of life to patient experience and trial retention
Biomarkers remain a critical measurement in almost every clinical trial, with this type of data facilitating the accurate characterisation of…
-
Ocugen sets sights on Phase III after GA gene therapy win
Ocugen has posted positive results for its lead investigational gene therapy, OCU410, in geographic atrophy (GA) secondary to dry age-related…
-
FDA and EMA release collaborative AI framework for drug development
In a bid to optimise the use of AI in drug development, US and European regulators have banded together to…
-
Akeso’s PD-1/CTLA-4 bispecific trumps chemo in frontline gastric cancer
Akeso’s cadonilimab has outperformed the activity of the current standard of care (SoC) treatment option during a real-world study in…
-
JPM26: Amgen touts MariTide’s weight loss, T2D potential off Phase II data
Amgen’s obesity and type 2 diabetes (T2D) hopeful, MariTide (maridebart cafraglutide), has demonstrated its once-quarterly dosing potential in a mid-stage…
-
Lynk’s selective JAK inhibitor claims Phase III RA win
Lynk Pharmaceuticals has posted positive topline results from a Phase III trial on its next generation Janus kinase 1 (JAK1)…
-
Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study
Eli Lilly’s best-selling weight loss drug, Zepbound (tirzepatide), has scored again, this time in a late-stage trial alongside the company’s…
-
J&J’s nipocalimab posts win in Phase II SLE trial
Johnson & Johnson’s (J&J) new star autoimmune drug, nipocalimab, has demonstrated its disease-modifying potential for systemic lupus erythematosus (SLE) in…
-
Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win
Zenas BioPharma’s lead autoimmune asset, obexelimab, met its primary endpoint in a Phase III trial; however, the data has failed…